Gain Therapeutics
Develops allosteric medicines and rexaceract for Parkinson’s disease.
Something off on this page? Send us feedback.
Profile
Develops allosteric drug candidates through its Magellan platform, centered on rexaceract for Parkinson’s disease. The clinical portfolio is concentrated in this orally administered GCase-targeting program.
Based in Bethesda, Maryland, research combines AI, physics-based methods, and supercomputing in the Magellan platform to identify allosteric binding sites and potential drug candidates. Discovery work spans neurodegenerative and lysosomal-storage diseases, metabolic disease, and solid tumors, while the clinical portfolio is centered on rexaceract, formerly GT-02287.
Rexaceract is an orally administered, brain-penetrant allosteric modulator intended to restore GCase function in Parkinson’s disease, with or without a GBA1 mutation. FDA authorization of the U.S. IND supports planned clinical development in the United States, Australia, and Europe. Progress depends on clinical execution, regulatory interaction, enrollment across that trial footprint, and advancing further Magellan-derived candidates.
Company facts
Key statistics
Year to date −44.3% · Average volume (30d) 477.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Dec 19, 2025 | Roth Capital | Target | $10 | |
| Dec 1, 2025 | H.C. Wainwright | Target | $8 | |
| Oct 7, 2025 | Maxim Group | Reiterate | Buy | $7 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.14 | −$0.11 | +20.3% | $33.3K | — | — | +16.38% |
| May 11, 2026Q1 FY26 | −$0.13 | −$0.13 | 0.0% | $33.3K | — | — | −1.10% |
| Mar 26, 2026Q4 FY25 | −$0.14 | −$0.11 | +21.4% | $25.0K | — | — | −3.17% |
| Nov 12, 2025Q3 FY25 | −$0.15 | −$0.15 | 0.0% | — | — | — | +1.36% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$4.4M | −$5.1M | −$4.8M | −$4.5M | −$5.4M | −$4.7M | |
| Net income | −$4.5M | −$5.8M | −$5.3M | −$4.5M | −$5.6M | −$4.7M | |
| Diluted EPS | −$0.16 | −$0.19 | −$0.15 | −$0.11 | −$0.13 | −$0.11 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $165.0K · FY22 $140.1K · FY23 $55.2K · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $13.1M · Total debt $609.9K · Total assets $15.4M · Shareholders' equity $11.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 42.65M · Float 41.65M · 97.6% free float
Insiders — no current Form 4 position.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Marshall Wace, LLP | 1.77M | 4.15% | 13F | May 15, 2026 |
| Potomac Capital Management, Inc. | 1.01M | 2.36% | 13F | May 14, 2026 |
| Jones Financial Companies LLLP | 631.6K | 1.48% | 13F | May 15, 2026 |
| Cambridge Investment Research Advisors, Inc. | 568.6K | 1.33% | 13F | Apr 30, 2026 |
| Dme Capital Management, LP | 566.1K | 1.33% | 13F | May 15, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Denali Therapeutics
LRRK2-PD and GCase Parkinson’s programs overlap directly
- AbbVie
24-hour subcutaneous levodopa infusion for advanced Parkinson’s disease
- Amneal Pharmaceuticals
Approved oral carbidopa/levodopa extended-release Parkinson’s therapy
- Supernus Pharmaceuticals
Wearable infusion treatment for advanced Parkinson’s motor fluctuations
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Gain Therapeutics | $1.77 | 0.00% | $75.5M | — | — | — | — |
| Denali Therapeutics | $24.00 | +0.04% | $3.81B | — | — | 1,056.9 | — |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Amneal Pharmaceuticals | $17.54 | 0.00% | $5.60B | 36.0 | 16.9 | 1.8 | +9.9% |
| Supernus Pharmaceuticals | $44.58 | +1.87% | $2.54B | — | 15.1 | 3.1 | +32.4% |
| Median | 54.0 | 16.8 | 5.0 | +10.2% |